Various trocars and trocar supports are provided for allowing an insufflation port on the trocar to be coupled through the trocar support to an insufflation fluid. In one embodiment, the trocar includes a housing, a cannula extending through the housing, and an insufflation port projecting from the housing. A trocar support is provided having an opening that receives the insufflation port on the housing such that the insufflation port is unobtrusive during use and can be connected and disconnected rapidly.
A system includes a catheter, an electrocardiogram (ECG) system, and a processor. The catheter is configured to apply pacing to given tissue location inside a ventricle of heart of patient. The ECG system is configured to acquire a set of ECG signals generated in response to the pacing, wherein electrodes of the ECG system attached to the patient define respective directions in space relative to an origin located in the heart. The processor is configured to (i) calculate respective set of signal differences between the acquired set of ECG signals and reference set of ECG signals, (ii) calculate corresponding set of deviation vectors along the respective directions in space, the deviation vectors having amplitudes corresponding to the respective signal differences, (iii) using the deviation vectors, calculate direction vector from the given location to new ventricle location at which to apply the pacing, and (iv) indicate calculated direction vector to user.
Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions are described comprising conjugates of E. coli polysaccharide antigen O1, O2, O4, O6, O8, O15, O16, O18, O25, and O75 and further comprising O153 or O21 or both O153 and O21 covalently bound to a carrier protein for the prevention of invasive ExPEC disease.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Provided herein is a method of treating a subject who has multiple myeloma. A single infusion of chimeric antigen receptor (CAR)-T cells comprising an anti-BCMA CAR comprising a polypeptide is administered to the subject. In certain embodiments, the dose of CAR-T cells administered to the subject is from 1.0×105 to 5.0×106 of CAR-T cells per kilogram of the subject's mass. The method of treatment is effective in obtaining and maintaining minimal residual disease negativity status, as well as other beneficial clinical outcomes related to efficacy and safety.
A surgical stapler end effector assembly comprises a staple cartridge, an anvil, and a buttress assembly. The staple cartridge comprises a plurality of staples and a deck. The staple cartridge is operable to drive the staples through the deck. The anvil is movable from an open position toward the staple cartridge to reach a closed position. The anvil includes an underside having staple forming surface configured to receive staples driven through the deck. The buttress assembly comprises a buttress body, an adhesive material, and a plurality of reinforcement strands. The reinforcement strands are configured to engage one or more staples fired through the buttress body.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A system, includes (i) a processor, which is configured to receive, in a zone between first and second regions of an organ of a patient, one or more signals, at least a signal among the signals includes first and second components indicative of an electrophysiological (EP) property of the organ, and based on a relation between the first and second components, the processor is configured to estimate a location of at least a transition zone between the first and second regions, and (ii) a display, configured to display at least the estimated transition zone over a map of the organ.
A system includes a fixture, a laser assembly, and a positioning assembly. The fixture is configured to hold (i) a substrate of a distal-end assembly of a catheter and (ii) a lead placed on a given solder pad disposed on the substrate, the laser assembly is configured to emit a laser beam, and the positioning assembly is configured to move the fixture, with the substrate and the lead, relative to the laser assembly, so as to mark a soldering position, at which the lead is to be attached to the given solder pad, with a laser spot of the laser beam.
Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions.
Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions.
Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions.
Wherein R1, R2, R2a, R3, R3a, R4, and R4a are defined herein.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
The disclosure relates to prostate neoantigens, polynucleotides encoding them, vectors, host cells, recombinant virus particles, vaccines comprising the neoantigens, proteinaceous molecules binding the prostate neoantigens, and methods of making and using them.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
Herein are antibodies or antigen-binding fragments specifically binding to GPRC5D. Additionally, monovalent antibodies or antigen-binding fragments specifically binding to GPRC5D are also included. The Fc region of these antibodies contains K248E and T437R mutations (designated as “RE mutations”) per the EU numbering system. The described antibodies, expressed in host cells that lack fucosylation capabilities, exhibit enhanced antibody-dependent cellular cytotoxicity (ADCC) and enhanced complement-dependent cytotoxicity (CDC).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present invention relates to improved pharmaceutical compositions comprising one or more bioconjugate compositions. Each bioconjugate composition comprises a mixture of mono-glycosylated and multi-glycosylated bioconjugates of specific E. coli O-antigen polysaccharide covalently coupled to a Pseudomonas aeruginosa Exoprotein A carrier protein. The invention further relates to a process for the production of purified bioconjugates from Gram-negative host cells and to bioconjugates obtained or obtainable by said process.
A system may include an emitter. The emitter may be configured to generate and/or apply sound waves, for example to a first end of a patient's bone. The emitter may be one or more of a surface transducer, a sound emitter, a speaker, and/or a piezoelectric device. The system may additionally, or alternatively, include a receiver. The receiver may be configured to detect sound waves, for example at a second end of the bone. For example, the receiver may detect sound waves (e.g., at the second end of the bone) after the sound waves propagate through the bone. The receiver may be one or more of a microphone, a piezoelectric device, and/or an accelerometer.
An endoscopic imaging system for use in a light deficient environment includes an imaging device having a tube, one or more image sensors, and a lens assembly including at least one optical elements that corresponds to the one or more image sensors. The endoscopic system includes a display for a user to visualize a scene and an image signal processing controller. The endoscopic system includes a light engine having an illumination source generating one or more pulses of electromagnetic radiation and a lumen transmitting one or more pulses of electromagnetic radiation to a distal tip of an endoscope.
G06T 7/521 - Depth or shape recovery from laser ranging, e.g. using interferometryDepth or shape recovery from the projection of structured light
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
A61B 1/04 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor combined with photographic or television appliances
A61B 1/05 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor combined with photographic or television appliances characterised by the image sensor, e.g. camera, being in the distal end portion
A61B 1/06 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor with illuminating arrangements
H04N 5/272 - Means for inserting a foreground image in a background image, i.e. inlay, outlay
H04N 13/239 - Image signal generators using stereoscopic image cameras using two 2D image sensors having a relative position equal to or related to the interocular distance
H04N 23/10 - Cameras or camera modules comprising electronic image sensorsControl thereof for generating image signals from different wavelengths
H04N 23/13 - Cameras or camera modules comprising electronic image sensorsControl thereof for generating image signals from different wavelengths with multiple sensors
H04N 23/45 - Cameras or camera modules comprising electronic image sensorsControl thereof for generating image signals from two or more image sensors being of different type or operating in different modes, e.g. with a CMOS sensor for moving images in combination with a charge-coupled device [CCD] for still images
H04N 23/56 - Cameras or camera modules comprising electronic image sensorsControl thereof provided with illuminating means
H04N 23/74 - Circuitry for compensating brightness variation in the scene by influencing the scene brightness using illuminating means
H04N 23/741 - Circuitry for compensating brightness variation in the scene by increasing the dynamic range of the image compared to the dynamic range of the electronic image sensors
H04N 23/84 - Camera processing pipelinesComponents thereof for processing colour signals
H04N 25/533 - Control of the integration time by using differing integration times for different sensor regions
21.
STAPLE CARTRIDGE RETENTION FEATURES FOR SURGICAL STAPLER
An apparatus includes an end effector, a staple cartridge retainer, and a staple cartridge datum locator. The end effector includes a first jaw, a second jaw, a knife sled, and a replaceable staple cartridge. The first jaw can selectively couple with the replaceable staple cartridge and the knife sled can actuate along a firing stroke to cut and staple tissue captured by the first and second jaws. The staple cartridge retainer is located along a distal portion of the end effector and includes a resilient retention body that can inhibit the replaceable staple cartridge from disassociating with the first jaw. The staple cartridge datum location is located along a proximal portion of the end effector and can position the replaceable staple cartridge at its predetermined datum location when the first and second jaw are in a closed position.
The invention relates to pharmaceutical compounds and pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds as inhibitors of the SMARCA2 protein and to its use in the treatment of SMARCA4 deficient cancers, e.g., SMARCA4 deficient non-small cell lung cancer (NSCLC).
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
An orthopedic fixation system includes a fastener configured to secure a first bone with a second bone whereby the fastener stabilizes the first bone relative to the second bone. The fastener includes an elastic component that provides the fastener with the ability to accommodate relative motion between the first bone relative to the second bone.
A method of constructing a detachment system for delivering an implantable medical device to a target location of a body vessel is presented. The method includes forming a compressible portion on a distal tube, engaging an implantable medical device with an engagement system, extending the engagement system through the distal tube such that the implantable medical device is distal of a distal end of the distal tube, applying a force to the engagement system to compress the compressible portion to a compressed state, fixing the engagement system to the distal tube to maintain the compressed state of the compressible portion, and joining a proximal end of the distal tube to a distal end of a proximal tube. The engagement system can include a loop wire that is fixed to the distal tube and engages the medical device.
A61B 17/12 - Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
A61B 17/00 - Surgical instruments, devices or methods
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
A61F 2/95 - Instruments specially adapted for placement or removal of stents or stent-grafts
In one exemplary mode, an apparatus includes a catheter including an electrode to provide an intracardiac electrogram (IEGM) signal and a signal used to sense impedance, an ablation energy generator configured to conduct ablative energy to the electrode of the catheter based on user input, a controller configured to sample the IEGM signal from the electrode before and after a given ablation, and sense impedance between the electrode and tissue, and a processor configured to compare the sensed impedance with a TPI threshold to determine a contact status of the electrode with respect to the tissue, render to a display an indication of the determined contact status, compute a change in the IEGM signal due to the given ablation, and adjust the TPI threshold for subsequent ablations based on the computed change in the IEGM signal due to the given ablation of the tissue with the electrode.
An apparatus includes a shaft and an end effector at a distal end of the shaft. The end effector has a distal end and a proximal end with a longitudinal intermediate point between the distal and proximal ends. The end effector is sized to fit in an anatomical passageway within a cardiovascular system. The end effector includes at least one sensor electrode and a reference electrode. The at least one sensor electrode is configured to contact cardiovascular tissue and thereby pick up potentials. The reference electrode is configured to pick up a potential from fluid in contact with the reference electrode. The reference electrode is located proximal to the longitudinal intermediate point of the end effector. The end effector is configured to prevent the reference electrode from contacting tissue.
A61B 18/12 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/287 - Holders for multiple electrodes, e.g. electrode catheters for electrophysiological study [EPS]
A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
29.
TECHNOLOGIES FOR CONTROLLING A RADIO FREQUENCY MODE OF ENERGY-BASED SURGICAL INSTRUMENTS
A control method for an energy-based surgical instrument includes activating energy at a subtherapeutic level, measuring a system response at the subtherapeutic level, adjusting one or more parameters based on the system response, and then activating energy at a therapeutic level according to the determined parameters. Tissue pad wear of the surgical instrument may be determined based on ultrasound usage of the instrument, and radio frequency (RF) energy output parameters may be determined based on the tissue pad wear. Attributes of an RF sealing operation may be recorded, and one or more control parameters of an ultrasonic transection operation may be determined based on the attributes of the RF sealing operation. Other embodiments are described and claimed.
A61B 18/12 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
30.
SURGICAL INSTRUMENT WITH HOVER SENSOR AND RELATED METHODS
A robotic surgical system, including: a robotic arm including a distal end; a tool driver operatively coupled with the distal end of the robotic arm; a control unit; a surgical instrument including: an end effector configured to transmit therapeutic energy to tissue via a therapeutic energy cycle based on instructions from the control unit; and an tissue sensor configured to determine at least one tissue characteristic and transmit the at least one tissue characteristic to the control unit, wherein the control unit is configured to modify the therapeutic energy cycle based on the at least one tissue characteristic; and a control console including: an activation switch configured to activate the therapeutic energy cycle, and a hover sensor configured to sense an object within a hover zone, wherein the hover sensor is configured to activate the tissue sensor to determine the at least one tissue characteristic.
A surgical instrument including a first jaw that is configured to support a staple cartridge therein. An axially movable firing member is configured to move between a beginning position and an ending position by a first flexible drive member and a second flexible drive member. A firing member lock is configured to prevent the firing member from distally moving from the beginning position to the ending position unless an axially movable camming member in the staple cartridge that is supported in the first jaw is in a starting position.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
The invention relates to pharmaceutical compounds and pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds as inhibitors of the SMARCA2 protein and to its use in the treatment of SMARCA4 deficient cancers, e.g., SMARCA4 deficient non-small cell lung cancer (NSCLC).
C07D 217/14 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/10 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 411/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 489/10 - Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
C07D 491/052 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/5355 - Non-condensed oxazines containing further heterocyclic rings
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
The present invention provides materials and methods for viral engineering, including the production of vectors and viral particles useful in, for example, gene therapy.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosure relates to methods of treating metastatic castration-resistant prostate cancer (mCRPC) in a subject, comprising administering to the subject (a) apalutamide, and (b) Compound 1, or a pharmaceutically acceptable salt thereof, including those methods wherein the mCRPC in the subject has been determined to be resistant to one or more androgen receptor signaling inhibitors (ARSI), including, for example, abiraterone acetate.
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
RR)-N-(2-(4-(4-cyclopropylpiperazin-l-yl)piperidin-l -yl)-5-((6-(3-(3,5- difluorophenyl)isoxazolidin-2-yl)pyrimidin-4-yl)amino)-4-methoxyphenyl)acrylamide, or a pharmaceutically acceptable salt thereof, in combination with amivantamab.
09 - Scientific and electric apparatus and instruments
Goods & Services
Scientific instruments, namely, electronic analyzers for testing and analyzing chemical and biological substances for the presence, absence, or quantity of biomarkers
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, including but not limited to leukemia.
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
42.
COMBINATIONS COMPRISING A MENIN-MLL INHIBITOR AND A BCL-2 INHIBITOR
Disclosed are combinations comprising a therapeutically effective amount of a menin-MLL inhibitor of Formula (I) or a pharmaceutically acceptable salt or a solvate thereof; and a therapeutically effective amount of a BCL-2 inhibitor; and optionally, a therapeutically effective amount of at least one other antineoplastic agent. Also disclosed are methods for treating a subject who has been diagnosed with a hematopoietic disorder using such combinations. Compounds are represented by Formula (I) as follows:
Disclosed are combinations comprising a therapeutically effective amount of a menin-MLL inhibitor of Formula (I) or a pharmaceutically acceptable salt or a solvate thereof; and a therapeutically effective amount of a BCL-2 inhibitor; and optionally, a therapeutically effective amount of at least one other antineoplastic agent. Also disclosed are methods for treating a subject who has been diagnosed with a hematopoietic disorder using such combinations. Compounds are represented by Formula (I) as follows:
Disclosed are combinations comprising a therapeutically effective amount of a menin-MLL inhibitor of Formula (I) or a pharmaceutically acceptable salt or a solvate thereof; and a therapeutically effective amount of a BCL-2 inhibitor; and optionally, a therapeutically effective amount of at least one other antineoplastic agent. Also disclosed are methods for treating a subject who has been diagnosed with a hematopoietic disorder using such combinations. Compounds are represented by Formula (I) as follows:
wherein the variables are defined herein.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
A61P 35/02 - Antineoplastic agents specific for leukemia
43.
SYSTEMS AND METHODS FOR MANUFACTURING AN ULTRASOUND CATHETER TIP
Methods may include disposing a first ultraviolet (UV) adhesive in a first portion of a cavity of a mold. Methods may include disposing an electro acoustic module (EAM) in the first UV adhesive in the cavity. Methods may include disposing a second UV adhesive in a second portion of the cavity of the mold to encapsulate at least a portion of the EAM disposed therein. Methods may include causing UV light to irradiate at least a portion of the mold. The UV light may cause at least the EAM, the first UV adhesive, and the second UV adhesive to form at least a portion of a catheter tip.
A catheter configured to be used in a medical procedure includes a shaft and electrically conductive splines. The splines can include an insulated portion and a non-insulated portion configured to electrically ablate tissue. The catheter can include one or more electrodes coupled to insulated portion(s) of the splines and configured to sense electrical signals in the tissue. The splines can be coupled to an apex, forming an expandable distal-end assembly. The catheter can include a bump stop coupled to the apex and configured to maintain a minimal distance between the apex and the distal tip of the shaft. An ablation system can include the catheter, a generator, and a processor configured to control ablation energy from the generator to the splines such that ablation energy is applied to a first spline without applying ablation energy to a second spline.
An end effector for a surgical tool includes opposing first and second jaws, the first jaw including an electrode, and one or more isolation bumps formed on an inner surface of the electrode. Each isolation bump includes a pillar extending from the inner surface of the electrode and terminating in a plateau surface, and a curable material applied to and protruding from the plateau surface, wherein the one or more isolation bumps help define a jaw gap between the opposing first and second jaws when the opposing first and second jaws are moved to a closed position.
A61B 17/00 - Surgical instruments, devices or methods
A61B 17/29 - Forceps for use in minimally invasive surgery
A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
46.
SURGICAL TRAINING DEVICE WITH DIGITAL FEEDBACK AND AUGMENTED REALITY GUIDANCE
A modular, ergonomic training system designed to teach and evaluate laparoscopic surgical skills through a collapsible frame featuring adjustable trocar ports that simulate real-world surgical scenarios for both right- and left-handed users. It includes a pegboard for attaching various training modules to practice tasks like object manipulation, precision cutting, and suture tying. The system integrates augmented reality (AR) and artificial intelligence (AI) for real-time, step-by-step guidance and performance analysis. AR overlays on a live video feed from a tablet mounted on the frame offer visual instructions, while AI algorithms evaluate metrics such as precision and technique, providing personalized feedback and automated skill assessment. Additional features include a rechargeable light source that mimics clinical lighting and reflective surfaces for enhanced performance monitoring. The system enables efficient, scalable training with cloud-based data storage for tracking progress, supporting remote coaching and long-term skill development.
An automated surgical staple inspection system automatically generates surgical staple inspection data characterizing a set of staples fired into a test skin by stapling device in a staple test. An inspection processing device obtains one or more images of the set of staples and applies an object detection model to infer locations of the staples and respective classes of the staples indicating whether the staples are properly formed or have one or more identified defects. Based on the inferred locations, staples may be mapped to respective positions in an expected staple pattern to generate a staple map. A keypoint detection model furthermore operates to automatically identify a set of keypoints in each staple from which staple height may be determined. The inspection processing device may generate one or more digital reports based on the inspection data, which may be outputted to a user interface of a user device.
G06V 10/44 - Local feature extraction by analysis of parts of the pattern, e.g. by detecting edges, contours, loops, corners, strokes or intersectionsConnectivity analysis, e.g. of connected components
G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
G06V 10/774 - Generating sets of training patternsBootstrap methods, e.g. bagging or boosting
Disclosed are combinations comprising a therapeutically effective amount of a menin-MLL inhibitor of Formula (I) or a pharmaceutically acceptable salt or a solvate thereof; and a therapeutically effective amount of at least one other therapeutic agent which is a hypomethylating agent, a cytidine deaminase inhibitor, a DNA intercalating agent, a pyrimidine analog, a purine analog, a kinase inhibitor, a CD20 inhibitor, an IDH inhibitor, an immunomodulatory agent or a DHODH inhibitor. Also disclosed are methods for treating a subject who has been diagnosed with cancer using such combinations. Compounds are represented by Formula (I) as follows:
Disclosed are combinations comprising a therapeutically effective amount of a menin-MLL inhibitor of Formula (I) or a pharmaceutically acceptable salt or a solvate thereof; and a therapeutically effective amount of at least one other therapeutic agent which is a hypomethylating agent, a cytidine deaminase inhibitor, a DNA intercalating agent, a pyrimidine analog, a purine analog, a kinase inhibitor, a CD20 inhibitor, an IDH inhibitor, an immunomodulatory agent or a DHODH inhibitor. Also disclosed are methods for treating a subject who has been diagnosed with cancer using such combinations. Compounds are represented by Formula (I) as follows:
Disclosed are combinations comprising a therapeutically effective amount of a menin-MLL inhibitor of Formula (I) or a pharmaceutically acceptable salt or a solvate thereof; and a therapeutically effective amount of at least one other therapeutic agent which is a hypomethylating agent, a cytidine deaminase inhibitor, a DNA intercalating agent, a pyrimidine analog, a purine analog, a kinase inhibitor, a CD20 inhibitor, an IDH inhibitor, an immunomodulatory agent or a DHODH inhibitor. Also disclosed are methods for treating a subject who has been diagnosed with cancer using such combinations. Compounds are represented by Formula (I) as follows:
wherein the variables are defined herein.
A61K 31/4355 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 35/02 - Antineoplastic agents specific for leukemia
49.
IDENTIFYING AND INDICATING CARDIAC AREAS EXHIBITING PROGRESSIVELY SLOWING ACTIVATION (PSA)
A method includes receiving a cardiac signal that is sensed by electrodes at a location in a heart of a patient, the cardiac signal including signal components evoked by respective activations. The signal components in the cardiac signal are found and annotated. Respective time differences are calculated between the annotations and the corresponding activations. Based on the time differences, one or more cardiac tissue locations are identified, that demonstrate progressively slowing activation (PSA). An EP map of at least a portion of the heart is presented to a user, including providing a graphical indication of the one or more tissue locations that demonstrate the PSA.
Surgical instruments and control systems therefor are disclosed. A surgical instrument can comprise: a power circuit comprising a power source and a switch, a microcontroller coupled to the power circuit, a handle comprising an attachment portion, and a control circuit in signal communication with the microcontroller. The attachment portion can comprise a first electrical contact in signal communication with the microcontroller. The control circuit can comprise a sensor configured to detect an attachment state of the attachment portion. The control circuit can communicate the detected attachment state to the microcontroller, and the microcontroller can ignore signals from the first electrical contact when the control circuit communicates a detached state. The attachment portion can comprise a second electrical contact coupled to a second power circuit, and the second power circuit can decouple the second electrical contact and the second power source when the sensor detects the detached state.
A61B 17/072 - Surgical staplers for applying a row of staples in a single action, e.g. the staples being applied simultaneously
A61B 17/00 - Surgical instruments, devices or methods
A61B 17/29 - Forceps for use in minimally invasive surgery
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
Fibronectin type III domains (FN3) that specifically bind to CD8A, related polynucleotides capable of encoding CD8A-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, and detectably labeled FN3 domains are useful in therapeutic and diagnostic applications.
The present disclosure provides compounds that are capable of modulating the activity of the interleukin-23 receptor (IL-23R). The present disclosure further provides corresponding pharmaceutical compositions, methods and/or uses for treatment of autoimmune inflammation and related diseases and disorders.
An ocular needle guide for access into a space below a sclera of an eye comprises a housing. The housing has a contact surface and a needle guide surface. The contact surface defines a cavity within the housing. The contact surface extends at least partially along a contact plane. The needle guide surface extends about a needle axis to define a needle guide channel. The needle guide channel extends through the housing to an opening defined by the contact surface such that the needle guide channel opens to the cavity via the opening. The needle axis is substantially parallel to the contact plane. The contact surface is shaped such that when the ocular needle guide is positioned on the eye, a portion of the sclera is positioned within the cavity, and a surface of the eye contacts and takes a shape of the contact surface.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
A61B 17/30 - Surgical pincettes, i.e. surgical tweezers
An apparatus includes an elongate flexible shaft and an end effector. The shaft has a proximal end and a distal end. The end effector is positioned at a distal end of the shaft. The end effector includes a body, an electrode, and a bonding material. The electrode defines one or more laterally oriented openings. The bonding material secures the electrode to the body. A portion of the bonding material is disposed in at least one of the one or more laterally oriented openings.
The disclosed technology includes an end effector of a medical device. The end effector includes a framework, a flexible circuit including electrodes, an insulative material, and skids. The framework and flexible circuits are disposed on the insulative material. The insulative material includes a first surface disposed a first height from the framework in a height direction of the end effector and includes a first dynamic coefficient of friction. The skids are disposed on the insulative material, each skid comprising a second surface disposed a second height from the framework in the height direction and including a second dynamic coefficient of friction, lower than the first dynamic coefficient of friction. The first surface and the skids are disposed in the height direction such that the first height and each respective second height are one of equal or the respective second height is greater than the first height.
A catheter is presented having a planar end effector with elongated ablation electrodes configured to provide electrical signals to achieve IRE in target tissue. The planar end effector can be aligned along a longitudinal axis of a shaft of the catheter and configured to flex away from the longitudinal axis when making contact with tissue. Bipolar electrical signals can be applied between the elongated ablation electrodes in various pair combinations to achieve PFA. The end effector may also include diagnostic electrodes configured to receive electrical signals from tissue to map tissue, pairs of tissue contact electrodes to determine which portions of the end effector are in contact with tissue, or reference electrodes configured to measure blood voltage.
A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
A61B 18/12 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
A61B 34/20 - Surgical navigation systemsDevices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
The disclosed technology includes a distal tip of a medical probe. The distal tip includes spines extending radially outward from a longitudinal axis of the end effector in an expanded configuration, a membrane connected to the spines, a first flexible circuit disposed on a first surface of the membrane proximate each of the plurality of spines, a second flexible circuit disposed on a second surface of the membrane proximate each of the plurality of spines, a plurality of first pairs of electrodes disposed on the first flexible circuit proximal to one another and a spine of the plurality of spines, and a plurality of second pairs of electrodes disposed on the second flexible circuit proximal to one another and a spine of the plurality of spines such that the first and second pairs of electrodes define a mirror image configuration.
The disclosed technology includes an end effector of a medical probe. The end effector includes spines and a membrane. The spines are coupled to a distal portion of a tubular member, with each spine including a proximal spine end coupled to the distal portion of the tubular member and a free distal end. The membrane and spines are fixed relative to each other to define a single member. The membrane defines a plurality of leaves, each of which, in an expanded configuration, extending curvilinearly outward and being separated from adjacent free distal ends of adjacent leaves of the plurality of leaves. Each leaf includes flexible circuits including electrodes.
The disclosed technology includes a flexible circuit for an end effector of a medical probe. The flexible circuit comprises a flexible substrate layer, a plurality of electrodes, and a stiffening layer. The stiffening layer is disposed on the first side of the flexible substrate layer and in the first zone of the flexible circuit such that a first thickness of a first zone of the flexible circuit is greater than a second thickness of the second zone of the flexible circuit, the thickness being measured along the vertical axis, and such that a first flexural rigidity of the first zone is greater than a second flexural rigidity of a second zone of the flexible substrate layer.
The disclosed technology includes an end effector comprising at least one flexible circuit extending along a longitudinal axis having a substrate supporting at least one electrical trace and at least one electrode. Portions of the substrate may be reinforced by forming the electrical trace with a plurality of bends and/or by providing a plurality of bends in the substrate. Additionally, portions of the substrate may include multiple layers, each layer having electrical traces which are offset from one another.
A system and method to identify flaws in a PCB wire assembly are disclosed. The method includes: capturing first and second images of an array of electrical wires aligned over tinned pads of the PCB, respectively prior-to and after, the joining of the wires to the tinned pads by an automated electrical connection system; classifying pixels of the first and second images to three categories including: category of pixels associated with tinned pads, category of pixels associated with PCB surface, and category of pixels associated with the wires; and identifying flaw in the wire assembly formed by the automated electrical connection system, based on a detected change in relative positioning of the pixels associated with the three categories between the first and second images. The method may further include rendering of the second image on a display together with a report indicative of existence of flaws in the wire assembly.
An apparatus includes a flexible catheter shaft, one or more electrodes, and one or more position sensors, at least one of the one or more position sensors being positioned on the distal portion of the catheter shaft, the one or more position sensors being configured to provide a signal indicating respective positions of the one or more position sensors in three-dimensional space in response to a magnetic field. The flexible catheter shaft includes a lumen in fluid communication with an open distal end of the shaft. The lumen is configured to receive a guidewire and to communicate a therapeutic fluid out through the open distal end. The shaft has an outer diameter ranging from approximately 0.67 mm to approximately 1.33 mm. At least one of the one or more electrodes is operable to apply electrical energy to tissue.
A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
A61B 18/06 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating caused by chemical reaction
A61B 34/20 - Surgical navigation systemsDevices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
64.
TECHNOLOGIES FOR CONTROLLING THERAPEUTIC AND SUBTHERAPEUTIC ACTIVATION OF ENERGY-BASED SURGICAL INSTRUMENTS
A control method for an energy-based surgical instrument includes activating an energy control signal at a subtherapeutic level, measuring a system response at the subtherapeutic level, adjusting one or more parameters based on the system response, and then activating an energy control signal at a therapeutic level according to the determined parameters. The subtherapeutic and therapeutic signals may be ultrasound or radio frequency (RF) energy and/or a combination of ultrasound and RF energy. Controlled parameters may include mode, cycle time, power (e.g., ultrasound tip displacement), or crest factor. Other embodiments are described and claimed.
A control method for an energy-based surgical instrument includes activating a combined radio frequency (RF) and ultrasound operation, which may be a sealing operation or a sealing and transection operation. The sealing operation includes activating a pulsed RF operation with an ultrasound sealing operation between pulses of the RF operation. A control method for the energy-based surgical instrument includes determining whether an ultrasonic blade of the surgical instrument contacts a tissue pad of the surgical instrument and, if so, allowing ultrasonic energy delivery at a reduced energy level or preventing ultrasonic energy delivery. Other embodiments are described and claimed.
A system includes an energy-based surgical instrument with a mode selector capable of selecting a latch mode and an automatic or non-latch mode. The surgical instrument may send a message signal indicative of the state of the mode selector to a surgical generator, which outputs an audio tone indicative of the state of the mode selector. The surgical instrument may generate feedback, such as haptic feedback, when energy delivery is nearly activated, and generate different feedback when the energy delivery is activated. The surgical instrument may measure tension applied at an end effector of the surgical instrument and generate haptic feedback based on the measured tension. Other embodiments are described and claimed.
An energy module is disclosed that includes a housing, a port mounted to the housing, a first emitter and a first receiver aligned with the first emitter, a second emitter and a second receiver aligned with the second emitter, and a control circuit in operable communication with the first emitter, the first receiver, the second emitter, and the second receiver. The control circuit is operable to emit a first beam from the first emitter toward the first receiver, emit a second beam from the second emitter toward the second receiver, and determine a type of surgical instrument coupled to the port based on the first receiver receiving or failing to receive the first beam and the second receiver receiving or failing to receive the second beam.
A61B 18/12 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
A61B 90/30 - Devices for illuminating a surgical field, the devices having an interrelation with other surgical devices or with a surgical procedure
A61B 90/90 - Identification means for patients or instruments, e.g. tags
G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
H01R 43/26 - Apparatus or processes specially adapted for manufacturing, assembling, maintaining, or repairing of line connectors or current collectors or for joining electric conductors for engaging or disengaging the two parts of a coupling device
H04B 5/72 - Near-field transmission systems, e.g. inductive or capacitive transmission systems specially adapted for specific purposes for local intradevice communication
H04L 49/25 - Routing or path finding in a switch fabric
H04L 67/10 - Protocols in which an application is distributed across nodes in the network
H04L 67/12 - Protocols specially adapted for proprietary or special-purpose networking environments, e.g. medical networks, sensor networks, networks in vehicles or remote metering networks
H04M 1/72406 - User interfaces specially adapted for cordless or mobile telephones with means for local support of applications that increase the functionality by software upgrading or downloading
H05K 5/00 - Casings, cabinets or drawers for electric apparatus
A system includes a control console, a laparoscopic instrument, and a uterine manipulator. The laparoscopic instrument includes a first proximity sensor element. The uterine manipulator includes a base and a shaft extending distally from the base. The shaft includes a distal end dimensioned to be inserted into the uterus of a patient and a second proximity sensor element located at the distal end. The proximity sensor elements are configured to cooperatively generate a distance signal indicating a distance between the proximity sensor elements. The control console is configured to receive the distance signal from either the first proximity sensor element or the second proximity sensor element and calculate a corresponding distance between the proximity sensor elements. The control console is configured to compare the corresponding distance with a threshold distance and generate an alert signal when the corresponding distance is smaller than the threshold distance.
An apparatus includes a first jaw (16) and a second jaw (618, 718, 900) that cooperate to clamp and staple tissue (90). The second jaw includes a jaw body (620, 720, 902) and a distal tip (619, 719, 906) pivotable relative to the jaw body between a first discrete and a second discrete position. First and second openings (663, 784, 785, 932, 934) are both defined by one of the distal tip or a structure (621, 920) located proximal to the distal tip. A projection (637, 781, 918) is defined by the other of the distal tip or the structure. The projection is positionable within the first opening (663, 785, 932) to releasably retain the distal tip in the first discrete position, and within the second opening (663, 784, 934) to releasably retain the distal tip in the second discrete position.
The invention relates to a rapid setting liquid lung sealant that forms a highly adherent and elastic hydrogel. Provided are lung sealants comprising two high molecular weight (20 kDa) multi-arm PEG compositions wherein the first PEG composition includes an alkaline buffer and the second PEG composition includes a mildly acidic buffer for optimized set up time and extended working time. In some embodiments, the PEGs further comprise a radioprotectant such as tocopherol. In some embodiments, a colorant is added to one or both PEGs of the lung sealant to improve visualization of the lung sealant against human lung tissue.
Disclosed is a medical probe comprising an elongated shaft extending along a longitudinal axis and a distal electrode disposed at a distal end of the elongated shaft, the distal electrode configured to deliver ablative energy to tissue. The medical probe includes an outer sleeve disposed at least partially around the elongated shaft and a plurality of planar members attached to the outer sleeve and extending radially outward from the longitudinal axis. Each planar member of the plurality of planar members comprises a framework coupled to an outer surface member and an inner surface member opposite the outer surface member. Each of the inner and outer surface members includes a plurality of electrodes diametrically disposed on the inner surface member and outer surface member and the outer sleeve is configured to move axially along the elongated shaft to move the plurality of planar members axially with respect to the distal electrode.
A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
72.
ELECTROPHYSIOLOGY CATHETER SYSTEM WITH COMPOSITE ELECTRODE BASED ON CONTACT FORCE AND IMPEDANCE SENSING FOR IRREVERSIBLE-ELECTROPORATION (IRE) AND RELATED METHODS
A catheter system for use with a catheter with a distal assembly supporting a plurality of electrodes adapted to sense electrical signal in heart tissue and a force sensor configured to generate first contact signals representative of a contact force acting on the distal assembly. The system includes an ablation power generator configured to energize the plurality of electrodes, an impedance circuitry configured to generate second contact signals representative of the electrodes in contact with tissue, a processor configured to receive the first and second contact signals and generate switch signals in response thereto, and a switch circuitry configured to connect in response to the switch signals solely selected electrodes in contact with tissue to the ablation power generator in forming one or more composite electrodes.
The disclosed technology includes a flexible circuit for an end effector of a medical probe. The flexible circuit includes a flexible substrate, electrodes, and a first sensing loop. The flexible substrate defines tines extending along a longitudinal axis. The electrodes are disposed on each of the tines. The first sensing loop is disposed on the flexible substrate. The first sensing loop forms one or more coils that generate a current that is indicative of a position of the one or more coils when the one or more coils is subjected to a magnetic field. The first sensing loop includes two segments disposed on respective tines extending generally parallel to the longitudinal axis and converging towards each other on a tine disposed on the longitudinal axis.
The disclosed technology includes an end effector comprising a plurality of spines extending along a longitudinal axis to define a basket assembly, the plurality of spines configured to bow radially outward from the longitudinal axis to define a radius of curvature with respect to the longitudinal axis and to transition between an expanded configuration and a collapsed configuration. Each spine of the plurality of spines can include a section extending radially outward from the radius of curvature defined by a remainder of each spine. The end effector can further include at least one electrode disposed on the section for each spine of the plurality of spines.
An apparatus for manufacturing an end effector for a basket catheter assembly includes a support platform and a force application mechanism. The support platform is configured to support an expandable basket formed of curved splines with shape retention. Guidelines pass through longitudinal channels of respective flexible sleeves and are connected to the free end of respective splines. The force application mechanism controllably applies and releases a tensile force on the second end of the guidelines. Pulling on a guideline applies a tensile force to the free end of the spline, thereby flattening it. This enables sliding the flattened spline through the longitudinal channel of the flexible sleeve. The spline reverts to a curved shape when the tensile force is released.
A method incudes receiving multiple tags along an ablation curve that covers a partial circumference over an inner wall of a cardiac chamber of a heart of patient. Using the tags, the ablation curve is completed to a full circumference over the inner wall to eliminate a conduction gap in the ablation curve.
An apparatus includes an elongate shaft assembly, an end effector, and a flexible circuit. The end effector includes one or more electrodes. The flexible circuit includes a flexible substrate and a trace. The flexible substrate includes a proximal portion, an intermediate portion, and a distal portion. The proximal portion of the flexible substrate is positioned proximal to the end effector. The intermediate portion extends along the distal portion of the shaft assembly and is positioned proximal to the end effector. The trace extends along at least the intermediate portion of the flexible substrate. A portion of the trace defines a position sensor that is configured to generate a signal in the presence of an alternating magnetic field and is configured to flex with the distal portion of the shaft assembly. The position sensor length is at least approximately 10 times greater than the outer diameter of the shaft assembly.
A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
An apparatus includes an elongate shaft assembly and a processor. The elongate shaft assembly includes a distal portion having an end effector and a tip member. The end effector has a flex circuit with a plurality of electrodes extending angularly about the distal portion of the shaft assembly and spaced longitudinally apart from each other along the distal portion of the shaft assembly. The tip member is positioned distal to the end effector and is more flexible than the distal portion of the shaft assembly. The processor is electrically coupled with the flex circuit and is configured to select one or more electrodes of the plurality of electrodes to activate. The processor is further configured to activate the one or more selected electrodes to apply electrical energy to tissue to thereby ablate the tissue.
A computer-implemented method provides real-time visual feedback of intraluminal catheter engagement within a luminal organ of a patient. A catheter with electrodes on a distal end assembly is positioned in the organ, and a three-dimensional (3D) model of the internal surface is generated and rendered as a 3D anatomical map. For each electrode, a proximity value indicative of distance to a tissue wall is determined based at least on measured impedance and translated into a graphical attribute value. A continuous proximity visualization feature is formed by sequencing the graphical attributes according to electrode positions, representing proximity variations. The feature is projected onto the 3D anatomical map, creating an integrated graphical representation displayed on a computer display. The visualization is dynamically updated in response to impedance changes, providing real-time feedback on catheter contact with the tissue wall.
A gap between a plurality of ablation sites in a heart that hinders electrical propagation therethrough is found by projecting the locations of the sites in a 3-dimensional coordinate system onto a simulation plane, identifying a set of shortest 3-dimensional paths that correspond to 2-dimensional connections between pairs of the projected locations of the sites, and reporting a gap as a longest one of the set.
A61B 17/00 - Surgical instruments, devices or methods
A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
A61B 18/12 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations
A61B 34/20 - Surgical navigation systemsDevices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
81.
TECHNOLOGIES FOR CONTROLLING CLAMPING FORCE OF A SURGICAL INSTRUMENT DURING AN OPERATION MODE
A surgical instrument and associated method for controlling clamping force of a surgical instrument includes an end effector having a jaw assembly movable between an open state and a closed state, a trigger assembly operable to move the jaw assembly of the end effector between the open state and the closed state, and a clamping force augmentation system controllable to increase a clamping force of the jaw assembly of the end effector. A controller of the surgical instrument is configured to activate the clamping force augmentation system to increase the clamping force of the jaw assembly of the end effector in response to an RF mode of the surgical instrument being activated and (ii) the position sensor indicating that the present state of the jaw assembly is in the closed state.
A surgical instrument and associated method includes an end effector having an ultrasonic blade, a metallic jaw clamp, and a partially conductive tissue pad coupled to the jaw clamp. The tissue pad comprises a polymeric substrate with a conductive trace formed on the surface of the polymeric substrate. The polymeric substate may be formed from polytetrafluoroethylene (PTFE), and the surface of the PTFE substrate may be treated to improve adhesion of the conductive trace. The tissue pad is erodible during activation of the ultrasonic blade. The conductive trace may be a multilayer laminate. A method for constructing the surgical instrument includes forming the conductive trace on the surface of the polymeric substrate and securing the polymeric substrate to the metallic jaw clamp.
A control method for an energy-based surgical instrument includes activating a subtherapeutic radio frequency (RF) signal, activating a stage of an ultrasonic operation, measuring a tissue parameter with the subtherapeutic RF signal, determining whether the tissue parameter exceeds a predetermined threshold, and activating another stage of the ultrasonic operation in response to determining that the tissue parameter exceeds the predetermined threshold. A control method includes measuring a mechanical parameter of the surgical instrument and adjusting delivery of therapeutic energy based on the mechanical parameter and a tissue parameter. Other embodiments are described and claimed.
A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
84.
TECHNOLOGIES FOR SEGMENTED ELECTRODES FOR ENERGY-BASED SURGICAL INSTRUMENTS
A system includes an energy-based surgical instrument with an end effector having one or more jaw clamps. The end effector may include a segmented electrode with a distal portion and a proximal portion coupled to one jaw clamp and a return electrode coupled to the other jaw clamp. The distal and proximal portions may be separately or cooperatively energized with radio frequency (RF) energy. A pressure varying mechanism may selectively limit or increase pressure at the distal portion of the electrode. The end effector may include a jaw clamp with a tissue pad positioned within a channel. The end effector may include a conformal or erodible electrode that extends to the distal tip of the jaw assembly. Other embodiments are described and claimed.
A system includes an energy-based surgical instrument with an end effector having two electrodes. One of the electrodes has multiple electrode portions. A generator coupled to the surgical instrument supplies radio-frequency (RF) energy to an electrode portion for a tissue coagulation process and further supplies RF energy at a higher voltage or current to another electrode portion for a tissue transection process. A control element may monitor tissue impedance or tissue temperature. Other embodiments are described and claimed.
A61B 18/12 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
Provided is a method for managing radio frequency (RF) and ultrasonic signals output by a generator that includes a surgical instrument comprising an RF energy output and an ultrasonic energy output and a circuit configured to receive a combined RF and ultrasonic signal from the generator. The method includes receiving a combined radio frequency (RF) and ultrasonic signal from a generator, generating a RF filtered signal by filtering RF frequency content from the combined signal; filtering ultrasonic frequency content from the combined signal; generating an ultrasonic filtered signal; providing the RF filtered signal to the RF energy output; and providing the ultrasonic filtered signal to the ultrasonic energy output.
A61B 18/12 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
A61B 17/00 - Surgical instruments, devices or methods
Drug delivery devices and methods are provided for administering gemcitabine to a patient in need of treatment of bladder cancer by intravesically administering gemcitabine into the bladder of the patient to achieve a sustained concentration of the gemcitabine in urine in the bladder sufficient to produce a therapeutically effective concentration of the gemcitabine in the tissues of the bladder. In embodiments, the local administration into the patient's bladder is at a mean average amount of from 1 mg/day to about 300 mg/day of the gemcitabine (FBE).
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
A61P 13/10 - Drugs for disorders of the urinary system of the bladder
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Described herein are T-cell receptors (TCRs) that bind to CALR or JAK2 antigens. Also described are T-cell receptors (TCRs), polynucleotides, vectors that encode the TCRs, and cells comprising the TCRs, and methods of treatment.
Provided herein are isolated mutant influenza hemagglutinin polypeptides, methods for providing isolated mutant influenza hemagglutinin polypeptides, methods of use of the isolated mutant influenza hemagglutinin polypeptides as a diagnostic or for the isolation of antibodies, compositions comprising the same, vaccines comprising the same and methods of their use, in particular in the detection, prevention and/or treatment of influenza.
Medical device in the nature of a proprietary outer surface as an integral component for artificial breast implants and artificial breast tissue expanders
92.
Systems and methods for performing ablation with a left atrial appendage implant device
Described herein are examples of a left atrial appendage (“LAA”) occlusion or elimination implant device further configured to ablate tissue located at an atrium of the heart or nearby veins and ostia. The implant device can be delivered to a patient's heart using a catheter system and includes a contact member comprising one or more electrodes. In use, the electrodes of the contact member can perform unipolar or bipolar ablation at an ablation site that is distinct from an ostium or interior of the LAA. The implant device can then be re-positioned at least partially within the LAA, and the contact member can be implanted to occlude or eliminate the LAA. The implant device can further include a securing element comprising one or more electrodes, the securing element configured to cooperate with the contact member in performing unipolar or bipolar ablation and/or occluding or eliminating the LAA.
A61B 17/12 - Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
A61B 18/16 - Indifferent or passive electrodes for grounding
93.
Surgical stapler with discretely positionable distal tip
An apparatus includes a first and second jaws (1404, 1406) that cooperate to clamp and staple tissue. The second jaw includes a jaw body (1408) and a distal tip (1410A, 1410B) pivotable relative to the jaw body between first and second discrete positions. The apparatus further includes first and second stops (1602, 1702A, 1702B, 1702C) configured to constrain the pivotable motion of the distal tip (1410A, 1410B), and a spring (1422) configured to exert a resilient force against a proximal protrusion (1414) of the distal tip in a first direction when in the first position and exert the resilient force against the proximal protrusion in a second, different, direction, when in the second position, the direction of the resilient force of the spring exerted against the proximal protrusion transitioning from one of the first and second directions to the other when the distal tip is transitioned between positions.
The present invention provides methods for treatment of high-risk non-muscle invasive bladder cancer that is unresponsive to BCG therapy by locally administering gemcitabine to the bladder. Also provided herein are kits and articles of manufacture for treating high-risk non-muscle invasive bladder cancer that is unresponsive to BCG.
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
Methods of measuring the amount of singly- or multiply-phosphorylated p217+ tau protein in a sample are provided. Methods of detecting or diagnosing tauopathies, methods of determining the effectiveness of a treatment of a tauopathy, and methods of determining whether a subject is suitable for anti-p217+ tau antibody therapy are also provided. Also described are antibodies for use in the methods and kits comprising the antibodies.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase
A system is disclosed that comprises an ablation probe that includes an antenna and a controller operable to receive an input indicative of a desired region to ablate with the ablation probe and automatically determine a proposed position of the ablation probe within the patient based on the input.
A61B 18/18 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
A61B 34/00 - Computer-aided surgeryManipulators or robots specially adapted for use in surgery
A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations
97.
ANNOTATION OF LATE POTENTIALS COMPRISING LOCAL ABNORMAL VENTRICULAR ACTIVATION (LAVA) SIGNALS
A method includes receiving a bipolar signal sensed by a pair of electrodes at a location in a heart of a patient. One or more electrocardiogram (ECG) signals are received, sensed by body-surface electrodes attached to the patient. Two or more successive QRS complexes are identified in the bipolar signal. One or more activations are detected in the bipolar signal, which occur within a window-of-interest that begins at least a given time with respect to the identified QRS complexes. The detected activations are checked whether they are late potentials, by verifying whether (i) the activations do not coincide with a predefined event observed in the ECG signals, and (ii) the activations are repeatable in the successive QRS complexes. In response to deciding that at least one of the detected activations is a late potential, the latest of the at least one of the late potentials is visualized to a user.
A61B 5/366 - Detecting abnormal QRS complex, e.g. widening
A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
A61B 18/12 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
98.
APPLICATION OF TOPICAL SKIN ADHESIVE TO SURGICAL MESH
A system includes a surgical mesh having an upper side and a lower side, where the upper side includes a visual indicia pattern that extends longitudinally along the upper side, and the lower side is configured to adhere to a section of skin of a patient that surrounds a wound. The system further includes a topical skin adhesive configured to be applied to the upper side of the surgical mesh based on the visual indicia pattern. The topical skin adhesive is configured to cure within the surgical mesh to thereby form a protective layer over the wound.
A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
The present invention relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of PTPN2 and/or PTPN1, yet more in particular for the prevention or treatment of cancer or metabolic diseases. The present invention also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds as well as to said compositions or preparations for use as a medicine, more preferably for the prevention or treatment of diseases mediated by activity of PTPN2 and/or PTPN1, yet more in particular for the prevention or treatment of cancer or metabolic diseases. The present invention also relates to processes for the preparation of said compounds.
C07D 417/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A robotic surgical system, comprising: a robotic grasper having a first jaw movably secured to a second jaw; a user interface device (UID) comprising a first finger pad and an opposing second finger pad; and; one or more processors communicatively coupled to the UID and the robotic grasper and configured to control operation of the robotic grasper while a teleoperation mode is engaged, prevent the UID from controlling the robotic grasper in a non-teleoperation mode, and perform the following operations while the system is in the non-teleoperation mode: receive a synchronization sequence including: a first closing action on the first and second finger pads, and an opening action on the first and second finger pads occurring after the first closing action; and determine that, as a result of the synchronization sequence, that the UID is now in a matched relationship with the first and second jaws of the robotic grasper; and then transition the robotic surgical system into the teleoperation mode.
